Tuhura Biosciences and Kintara Therapeutics Announce Positive Results From Phase 1B Trial of Ifx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (Mcc) and Cutaneous Squamous Cell Carcinoma (Cscc)
Tuhura生物和kintara therapeutics宣佈，Ifx-2.0的1B期臨床試驗的結果是積極的。 Ifx-2.0是一種新型個性化癌症生物-疫苗，用於治療難治性晚期Merkel細胞癌（Mcc）和表皮鱗狀細胞癌（Cscc），患者之前使用過PD-1、PD-L1等檢查點抑制劑治療但療效不佳。